Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.62 |
| ▸ | KISS1R | Q969F8 | 14/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973913 | 0.96 | NPBWR1 (0.65) | OPRM1OPRD1NPBWR1KISS1R | |
| SCHEMBL29973046 | 0.93 | KISS1R (0.62) | OPRM1OPRD1KISS1R | |
| SCHEMBL29425581 | 0.89 | KISS1R (0.59) | OPRM1OPRD1KISS1R | |
| SCHEMBL31442261 | 0.89 | OPRD1 (0.71) | OPRM1OPRD1NPBWR1KISS1R | |
| SCHEMBL29822493 | 0.88 | KISS1R (0.65) | KISS1R | |
| SCHEMBL29973245 | 0.87 | KISS1R (0.56) | OPRM1OPRD1KISS1R | |
| SCHEMBL30690358 | 0.86 | GLP1R (0.66) | OPRD1 | |
| SCHEMBL31232499 | 0.86 | GLP1R (0.68) | NPBWR1KISS1R | |
| SCHEMBL30690385 | 0.86 | OPRM1 (0.61) | OPRM1OPRD1NPBWR1KISS1R | |
| SCHEMBL30116700 | 0.86 | PRMT1 (0.61) | NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107246-A1 | SELECTIVE SENOLYTIC CELL PENETRATING PEPTIDE COMPOSITIONS AND USES | SENOTHERAPEUTIX, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4638483-A1 | GALANIN-2 RECEPTOR AGONISTS | LifeArc (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12263224-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240327339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024132147-A1 | GALANIN-2 RECEPTOR AGONISTS | LIFEARC (GB) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023143610-A2 | C-TERMINAL FRAGMENT OF APOLIPOPROTEIN E AND APPLICATION THEREOF IN INHIBITING γ-SECRETASE ACTIVITY | 斯莱普泰(上海)生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230201363-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2022170396-A1 | AGENTS AND METHODS FOR THERAPY AND PROPHYLAXIS | ViraLok Therapeutics Pty Ltd (AU) | 2022-08-18 | — | — | WO | disclosed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263224-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | OPRM1 3028/4885OPRD1 3434/4885NPBWR1 3603/4885 |
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | OPRM1 3028/4885OPRD1 3434/4885NPBWR1 3603/4885 |
| US-20240327339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ACE, ACE2, SARNP | OPRM1 2818/4885OPRD1 3335/4885NPBWR1 2808/4885 |
| US-20230201363-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MTPN, MYOF, TNNC1 | OPRM1 3028/4885OPRD1 3434/4885NPBWR1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.